IPCA Laboratories — 360° view

IPCA Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹2,910 crore and net profit of ₹389 crore for the September 2026 quarter.

IPCA Laboratories (NSE: IPCALAB) closed at ₹1,843.80 on 20 Nov 2026, up 28.2% over the past year. Its market capitalisation is ₹46,778 crore and it trades at 32.5 times earnings.

Share price
₹1,843.80 (20 Nov 2026)
Market cap
₹46,778 Cr (20 Nov 2026)
P/E
32.47 (20 Nov 2026)
Revenue
₹2,910 Cr (September 2026 quarter)
Net profit
₹389 Cr (September 2026 quarter)
ROCE
17.0% (FY26)
ROE
15.7% (FY26)
Book value
₹342 (FY26)
Dividend yield
0.33% (last 12 months to 20 Nov 2026)
52-week high / low
₹2,038.00 / ₹1,361.70 (20 Nov 2026)
1-year return
28.2% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: IPCALAB

Ipca Laboratories is an integrated pharmaceutical company manufacturing branded and generic formulations, APIs and intermediates. Indian branded formulations are its core profit engine, complemented by formulation exports across Europe, Africa, the Americas, Asia, CIS and Australasia. The consolidated business includes Unichem Laboratories and its US, Brazil, Europe and South Africa operations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.